Biotechnology News

REYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture...

REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar...

Alvotech birtir í dag uppgjör fyrir fyrstu sex mánuði ársins 2026 og fjallar um nýlega áfanga í rekstri félagsins. Ítarlegri útgáfu á ensku er að finna á vefsíðu félagsins fyrir fjárhagsupplýsingar:...

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential...

Longeveron has appointed Nirav Jhaveri, CFA, as Chief Financial Officer. He has over 25 years of experience in capital markets and corporate finance.

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics...

COPENHAGEN, Denmark – August 19, 2026. Novonesis delivered strong first half of 2026 at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% (previously 5-7%), and the...

Strong first half year at 8% organic sales growth. 2026 outlook: Organic sales growth increased to 7-8% and the adjusted EBITDA margin expected at the higher end of the 37-38% range. Inaugural share...

The Board of Directors of Novonesis has approved an inaugural multi-year share buyback program in a total amount of EUR 1 billion to be initiated during the second half of 2026 and expected to be...